Buying $1000 In REGN: If an investor had bought $1000 of REGN stock 20 years ago, it would be worth $57,109.53 today based on a price of $563.10 for REGN at the time of writing.

Regeneron presents an interesting investment case. Its valuation doesn't fully capture Dupixent's strength or its pipeline potential. Bears worry about Eylea's patent cliff, but this seems priced in.

Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a narrow economic moat. Growth of existing products and new product launches should help offset ...

Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here.

The atopic dermatitis market, valued at USD 9.33 billion in 2024, is projected to grow at a CAGR of 15.10%, reaching USD 38.07 billion by 2034. Key d ...

Key Points From the end of June through July 10, shares of ProKidney Corp. shot 775% higher.ProKidney is developing a ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Amgen's expanding rare disease and biosimilar portfolios, coupled with growth potential and dividend history make AMGN stock ...

Fujifilm delivered strong FY2025 results, driven by progress on VISION2030 and a diversified business mix. Read why FUJIY ...

Morgan Stanley slightly lowered its price target for Regeneron Pharmaceuticals while maintaining an overweight rating, ...

India's top stock exchanges, NSE and BSE's market prospects have suffered following regulatory actions which includes Jane Street ban.

On the other side, on July 7, JP Morgan analyst Chris Schott reiterated a Buy rating on Regeneron, while maintaining his $800 ...